Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 99.1 Slides Titled "Rezpegaldesleukin (Rezpeg) Corrected Phase 1B Dataset for Studies of Rezpeg In Atopic Dermatitis and Psoriasis"
- 99.2 Press Release Titled "Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported In 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company"
- Download Excel data file
- View Excel data file
NKTR similar filings
- 7 Nov 23 Nektar Therapeutics Reports Third Quarter 2023 Financial Results
- 8 Sep 23 Termination of a Material Definitive Agreement
- 8 Aug 23 Nektar Therapeutics Reports Second Quarter 2023 Financial Results
- 7 Aug 23 Regulation FD Disclosure
- 22 Jun 23 Departure of Directors or Certain Officers
- 9 Jun 23 Submission of Matters to a Vote of Security Holders
- 2 Jun 23 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
Filing view
External links